According to the ETF Finder at ETF Channel, CTIC makes up 1.00% of the SPDR S&P Biotech ETF (XBI) which is lower by about 0.1% on the day Thursday.
In afternoon trading Thursday, CTIC was up about 1% on the day.
TheStreet's biotech columnist offers his own report card on biotech stocks.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Stocks with insider trader activity include LPNT, PATK and CTIC